Samsung Biologics Co., Ltd.

Samsung Biologics is an end-to-end CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry.

With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products.

Our plants are cGMP compliant with a wide range of bioreactor scales. We are committed to maximizing operational efficiency and enhancing our development and manufacturing capabilities to meet growing market demand. Upon full completion of Plant 4 in the first half of 2023, we will hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and account for one-fourth of the global CDMO manufacturing capacity.